Neurology Central

Novel Alzheimer’s drug shows positive results in Phase III trial

Green Valley Pharmaceutical (Shanghai, China) has announced promising findings from a Phase III clinical trial of GV-971, a multi-targeting carbohydrate-based drug for the treatment of people with mild-to-moderate Alzheimer’s disease (AD).
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.